Cancer in Slovenia

IARC estimates 14,264 new cancer cases and 6,899 cancer deaths in Slovenia in 2024; the commonest new cancers are prostate, trachea, bronchus and lung and breast. This page is assembled automatically from OnCo's data: 28 trials with a site there, 2 institutions and 2 people, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

14,264

all cancers

Deaths

6,899

all cancers

Incidence rate

296.8

per 100,000, age-standardised

Mortality rate

113.9

per 100,000, age-standardised

Cumulative risk

29.4%

of a cancer by age 74

Population

2,118,702

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	1,804	72.4	Prostate cancer
Trachea, bronchus and lung	1,686	33.7	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Breast	1,655	81.3	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Colorectum	1,532	28.4	Colorectal cancer
Melanoma of skin	721	16.7	Melanoma
Bladder	700	12.4	Bladder & urothelial cancer
Pancreas	486	8.6	Pancreatic ductal adenocarcinoma
Non-Hodgkin lymphoma	468	10.1	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Stomach	413	7.3	Gastric & gastro-oesophageal junction cancer
Kidney	410	8.7	Renal cell carcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	1,264	23.6	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	722	10.8	Colorectal cancer
Breast	496	15.4	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	464	14.8	Prostate cancer
Pancreas	455	7.6	Pancreatic ductal adenocarcinoma
Liver and intrahepatic bile ducts	312	5.4	Hepatocellular carcinoma
Stomach	307	4.9	Gastric & gastro-oesophageal junction cancer
Bladder	274	3.6	Bladder & urothelial cancer
Leukaemia	256	3.9	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Non-Hodgkin lymphoma	252	3.7	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Slovenia”, in Southern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

28 trials in OnCo · 8 recruiting overall

28 trials

Trial			Lead sponsor
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other NCT06152575	Phase 3	Recruiting	Pfizer	270	2026-08-24
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) NCT07044336	Phase 3	Recruiting	AstraZeneca	320	2026-07-29
Neoadjuvant Darovasertib in Primary Uveal Melanoma NCT07015190	Phase 3	Recruiting	IDEAYA Biosciences	94	2026-05-06
Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study) NCT07432399	Phase 2	Recruiting	Institute of Oncology Ljubljana	1	2026-03-06
Electrochemotherapy for Recurrent Vulvar Cancer NCT07443475	Phase 2	Recruiting	Institute of Oncology Ljubljana	1	2026-03-02
Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer - NCT06923787	Phase 2	Recruiting	Institute of Oncology Ljubljana	2	2026-02-05
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) NCT04221035	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	142	2025-06-26
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer NCT05797831	Phase 2/3	Recruiting	Kartos Therapeutics, Inc.	83	2024-05-02
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer NCT05132075	Phase 3	Active not recruiting	Novartis Pharmaceuticals	51	2026-09-25
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) NCT06065748	Phase 3	Active not recruiting	Hoffmann-La Roche	311	2026-09-14
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612	Phase 2	Active not recruiting	Genentech, Inc.	179	2026-08-28
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) NCT03148418	Phase 3	Active not recruiting	Hoffmann-La Roche	170	2026-07-10
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML NCT03591510	Phase 2	Active not recruiting	Novartis Pharmaceuticals	15	2026-07-09
lidERA NCT04961996	Phase 3	Active not recruiting	Hoffmann-La Roche	622	2026-06-17
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib NCT04421963	Phase 3	Active not recruiting	AstraZeneca	107	2026-06-12
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets NCT07234877	Phase 2	Not yet recruiting	European Organisation for Research and Treatment of Cancer - EORTC	26	2026-06-04
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) NCT05566795	Phase 3	Active not recruiting	Day One Biopharmaceuticals, Inc.	138	2026-05-14
RAPIDO NCT01558921	Phase 3	Active not recruiting	University Medical Center Groningen	56	2026-05-01
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer NCT00066703	Phase 3	Completed	ETOP IBCSG Partners Foundation	228	2026-02-06
APHINITY NCT01358877	Phase 3	Completed	Hoffmann-La Roche	546	2025-11-28
IPATunity130 NCT03337724	Phase 3	Completed	Hoffmann-La Roche	176	2024-03-12
IMpassion130 NCT02425891	Phase 3	Completed	Hoffmann-La Roche	247	2022-07-19
SIOPEN HR-NBL1 NCT01704716	Phase 3	Unknown	St. Anna Kinderkrebsforschung	126	2020-10-23
RAISE NCT01183780	Phase 3	Completed	Eli Lilly and Company	213	2019-09-25
STEVIE (vismodegib in ordinary practice) NCT01367665	Phase 2	Completed	Hoffmann-La Roche	181	2019-06-06
IBCSG 23-01 NCT00072293	Phase 3	Completed	ETOP IBCSG Partners Foundation	31	2018-01-23
ROMANA 1 and ROMANA 2 NCT01387269, NCT01387282	Phase 3	Completed	Helsinn Therapeutics (U.S.), Inc	106	2017-10-27
AMAROS (EORTC 10981-22023) NCT00014612	Phase 3	Completed	European Organisation for Research and Treatment of Cancer - EORTC	29	2013-10-29

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Slovenia, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Slovenia is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

2 institutions

Institute of Oncology Ljubljana Slovenian Association of Psychosocial Oncology and Palliative Care

2 people

People whose main affiliation in OnCo is an institution or company in Slovenia.

Janja Ocvirk Zlata Štiblar Kisić

Approvals

Slovenia is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Slovenia's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Slovenia, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Slovenia's own sources.

Slovenia is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/si.json; every country: /api/v1/countries.json.